OCLS Aims to Clear Confusion Caused By Published Reports Print E-mail
By Peter DePalma   
Monday, 02 November 2009 03:00

Continuing their efforts to educate consumers after the "great deal of harm" that has been caused by one columnist's claims that Oculus Innovative Sciences' (NASDAQ:OCLS) products are little more than diluted bleach, the California based company has decided to deploy an "Investor Dialogue" page aimed at educating investors, consumers and the medical community.

On the new page, a column by Dr. Bob Northey, the company's director of R&D, discusses this issue in very specific and scientific terms. The company aims to clarify, once and for all, that Microcyn® is a safe, non-irritating oxychlorine compound designed to treat a range of pathogens in wounds.

"Occasionally, through a lack of understanding of chlorine chemistry, the Microcyn® Technology is erroneously described as dilute bleach," writes Northey. "Bleach is an alkaline solution (pH>11) of sodium hypochlorite (NaOCl) which is the sodium salt of hypochlorous acid (HOCl), the active ingredient in the Microcyn Technology. These two chemicals exist in a pH-driven equilibrium.  At pH 7.4, there are equal amounts of both chemicals in solution while at the alkaline pH of bleach the solution is greater than 99% sodium hypochlorite.  The chemical properties of these two compounds, and thus Microcyn® Technology and dilute bleach, are vastly different."

Calls from patients, doctors and investors prompted the company to take action. Some feel the website, TheStreet.Com, has repeatedly misrepresented facts about the company's product line, which a San Francisco area television station recently called a promising path to a major medical advance. Members of the medical community and patients who use Microcyn® products were adversely affected by the reports and company officials feared that these innacurate reports had become a patient safety issue which put public safety at risk.

After reviewing the material on the page, some chemists and scientists have contacted the company to lend their support and affirm that "everything in their clarification article is accurate."

One retired chemist from DuPont urged others to ignore the confusing misrepresentations. "The pseudo-scientific parts are nonsense. Don't place any trust in internet bloggers when they're scientifically in way over their heads. The internet is filled with gross oversimplification and erroneous assumptions and conclusions."

A growing number of publicly traded companies and investors have complained to the editorial staff at TheStreet.Com while others have been calling for an investigation into the nature and motives behind the misrepresentations and innacuracies. At least one group of concerned investors and consumers is actively organizing a movement to boycott the company's sponsors.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus